<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5467">
  <stage>Registered</stage>
  <submitdate>15/11/2006</submitdate>
  <approvaldate>15/11/2006</approvaldate>
  <nctid>NCT00400855</nctid>
  <trial_identification>
    <studytitle>Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate</studytitle>
    <scientifictitle>A Randomised, Double-blind, Placebo-controlled, Incomplete Block, 4-period Crossover, Study to Investigate the Effects of 5-day Repeat Inhaled Doses of Fluticasone Propionate (BID, 50-2000 mcg) on Airway Responsiveness to Adenosine 5-monophosphate (AMP) Challenge When Delivered After the Last Dose in Mild Asthmatic Subjects.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SIG103337</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Fluticasone propionate

Experimental: Arm 1 - study drug


Treatment: drugs: Fluticasone propionate
Study drug

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To characterise the dose response curve following repeat inhaled doses of FP for 5 days in the AMP challenge model.</outcome>
      <timepoint>5 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety following multiple AMP challenges: Adverse events</outcome>
      <timepoint>5 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentrations of FP and derived pharmacokinetic parameters</outcome>
      <timepoint>5 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Exhaled nitric oxide concentrations</outcome>
      <timepoint>5 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Female of non-childbearing potential

          -  Using appropriate contraception.

          -  Mild asthmatic, non (or ex) smokers.

          -  Has inflammatory response to AMP.

          -  Otherwise healthy, not using any steroids.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Have a history of life-threatening asthma, defined as an asthma episode, which
             required intubation and/or was associated with either hypercapnea, respiratory arrest
             or hypoxia seizures.

          -  Have a known sensitivity to corticosteroids.

          -  Have a history of milk protein allergy.

          -  Test positive at the screening visit for hepatitis B or C or HIV</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>49</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Inhaling AMP causes an inflammatory response in the lung. This study will investigate whether
      5-days of treatment with fluticasone propionate protects the lung from responding to the AMP
      in this way.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00400855</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>